A hidden lung cancer in a patient with granulomatosis with polyangiitis

CHENG XIE, CATRIONA STODDART, JAMES BEWES, HEIKO PESCHL, RAASHID LUQMANI and RACHEL BENAMORE

Department of Radiology, Churchill Hospital, Oxford University Hospital Trust, Old Road, Headington, Oxford, OX3 7LE, United Kingdom
Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford University Hospital Foundation Trust, Windmill Road, Headington, Oxford, OX3 7HE, United Kingdom

Address correspondence to: Dr Cheng Xie
E-mail: chengxie@doctors.org.uk

Summary

Granulomatosis with polyangiitis is a systemic necrotizing vasculitis that affects the small- and medium-sized blood vessels. The diagnosis can be challenging since the clinical and imaging findings have similarities with infection, and malignancy. Serologic and histopathological investigations often help confirm the diagnosis. However, this can be falsely reassuring. We present a unique case of the coexistence of vasculitis and squamous cell carcinoma in the same cavitating lung mass. The case highlights the importance of recognizing changes in disease behaviour early to allow for timely management.

Clinical presentation

A 78-year-old male was urgently referred by the General Practitioner with a 4 week history of productive cough, occasional haemoptysis and epistaxis with an abnormal chest X-ray showing a spiculated mass in the right lower zone (Figure 1). He had hypertension, and a previous history of treated tuberculosis infection. He was an ex-cigarette smoker. There were no significant findings on clinical examination.

Investigations

The CT scan of the thorax showed a cavitating mass in the right lower lobe (Figure 2a) with bilateral small cavitating nodules (Figure 2b). The patient had antineutrophil cytoplasm antibody (cytoplasmic pattern, cANCA) at a titre of 1/20 and a PR3 level of 14.6 IU ml⁻¹. The histopathology from the subsequent CT-guided biopsy of a representative sample of the right lower lobe mass revealed necrotizing granulomatous inflammation, but no evidence of malignancy. He was commenced on subcutaneous methotrexate with a good response both clinically and on imaging (Figure 3). After 3 months, the patient developed renal impairment, which was suspected to be due to a combination of disease progression and/or methotrexate nephrotoxicity. His treatment was switched to high dose intravenous pulses of cyclophosphamide and a tapering dose of oral prednisolone, which is shown to be effective in achieving remission in over 88% of patients within 9 months, and in accordance with European League Against Rheumatism recommendations.

After 3 months of cyclophosphamide treatment, the patient developed a new cough and his chest X-ray showed an increase in size of the right lower nodule (Figure 4). The clinical impression at this stage was a flare of the vasculitis. The CT confirmed a cavitating mass (Figure 5) at the same location as the initial CT. Over the next 6 months, the patient was treated with mycophenolate mofetil, rituximab, and further cyclophosphamide infusions, on the assumption that he had more resistant vasculitis. However, there was no improvement in his symptoms and he continued to lose weight. This raised the suspicion of an alternative cause and prompted another CT. The CT showed an enlarging lobulated mass at the same location in the right lower lobe with adjacent pleural involvement (Figure 6a). The corresponding PET-CT imaging demonstrated high avidity and central necrosis with right hilar lymphadenopathy (Figure 6b). A repeat biopsy of the mass revealed squamous cell carcinoma (SCC).

Differential diagnosis

The working diagnoses on presentation after the initial CT (Figure 2) were infection (including tuberculosis and aspergillosis), vasculitis and lung malignancy. Cavitating lesions, particularly in a peripheral and lower zone distribution are typical of vasculitis, but can also be caused by tuberculosis or SCC. Therefore, biopsy was required and in conjunction

© 2019 The Authors. Published by the British Institute of Radiology. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
with a positive ANCA, confirmed the diagnosis of granulomatosis with polyangiitis (GPA). After an initial apparent period of treatment response (3 months), he worsened, suggesting that his vasculitis was resistant and required a change in therapy. There were no indications to suggest an intercurrent infection. However, the inadequate disease control following 6 months of therapy with different immunosuppressant agents (including Rituximab) raised the concern that there might be another underlying cause.

**Outcome**

Following confirmation of SCC, the patient’s PET/CT confirmed a disease staging of T4N2M0. He was urgently referred to the lung cancer multidisciplinary team for further management.

**DISCUSSION**

GPA is a multisystem disorder of necrotizing vasculitis involving small and medium sized blood vessels and is typically found to be associated with the presence of ANCA. Pulmonary nodules with cavitation are the main radiological feature of GPA affecting the lungs. Lymphadenopathy is rare. Given the imaging similarities between vasculitis and malignancy, it has been well documented that vasculitis could mimic malignant tumours and infection (tuberculosis, aspergillosis), which can make the diagnosis challenging. There is also evidence that long-term treatment of vasculitis including the use of cyclophosphamide increases subsequent lung cancer risk. A case series reports the development of lung cancer within 2 years of treatment.

The patient in this case had positive serology and histopathology for GPA and responded well to treatment in the first 3 months. In retrospect, the short period of response to treatment before the malignancy progressed suggests the possibility of a coexistent malignant tumour at the same site as the vasculitis, rather than either resistant vasculitis or therapy-induced lung cancer. We suspect that the vasculitic component of the right lower lobe mass initially responded to therapy, and the residual nodule at the end of the 3 months treatment period (Figure 3) was the malignant component, which continued to grow despite different combinations of drugs targeting the vasculitis. An early CT was not performed because of initial improvement of the lung mass and other nodules. However, once a radiograph showed interval increase in size of the remaining nodule, reassessment of this
with a repeat CT was immediately recommended and done. We did not feel a contrast-enhanced CT would add any additional value since both vasculitic and malignant tumour would demonstrate contrast enhancement. To our knowledge, there have been one previous case report of a possible GPA coexistence with lung cancer.13 Although rare, our case highlights that we must remain vigilant in suspecting other potential causes, such as infection or malignancy, to explain an apparent early relapse or failure to respond to conventional immunosuppressive therapy even in patients who have a confirmed diagnosis of vasculitis.

**LEARNING POINTS**

1. Vasculitis could mimic malignant lung tumour and vice versa, and even co-exist at presentation.
2. Clinicians and radiologists should remain vigilant of any abnormal behaviour of the disease, even after serology and histopathology confirmation.
3. Early detection of any change in the disease behaviour should trigger discussion of the case at a multidisciplinary setting for further management.

**REFERENCES**

1. de Groot K, Harper L, Jayne DRW, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009; 150: 670–80. doi: [https://doi.org/10.7326/0003-4819-150-10-200905190-00004](https://doi.org/10.7326/0003-4819-150-10-200905190-00004)
2. Yates M, Watts RA, Rajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis* 2016; 75: 1583–94. doi: [https://doi.org/10.1136/annrheumdis-2016-209133](https://doi.org/10.1136/annrheumdis-2016-209133)
3. Lohrmann C, Uhl M, Kötter E, Burger D, Ghanem N, Langer M. Pulmonary manifestations of Wegener granulomatosis: CT findings in 57 patients and a review of the literature. *Eur J Radiol* 2005; 53: 471–7. doi: [https://doi.org/10.1016/j.ejrad.2004.04.016](https://doi.org/10.1016/j.ejrad.2004.04.016)
4. Blennerhassett JB, Borrie J, Lichter I, Taylor AJ. Localized pulmonary Wegener’s granuloma simulating lung cancer: report of four cases. *Thorax* 1976; 31: 576–84. doi: [https://doi.org/10.1136/thx.31.5.576](https://doi.org/10.1136/thx.31.5.576)
5. Rabahi MF, Coelho LB, Borges EdeO, Lemes MS, Castro WMde, Carneiro SdeS, Fouad-Rabahi M, Bertti-Coelho deO-BE, Stival-Lemes M, Mendes De Castro W, de Souza-Carneiro S. Lung pseudotumor as the initial presentation of Wegener’s granulomatosis. *J Bras Pneumol* 2009; 35: 392–5. doi: [https://doi.org/10.1590/s1806-37132009000400015](https://doi.org/10.1590/s1806-37132009000400015)
6. de Oliveira RV, Zanetti G, Marchiori E. Multiple pulmonary nodules. Wegener’s granulomatosis simulating pulmonary metastases. *QJM* 2013; 106: 1143–4. doi: [https://doi.org/10.1093/qjmed/hcs202](https://doi.org/10.1093/qjmed/hcs202)
7. Uppal S, Saravanappa N, Davis JP, Farmer CK, Goldsmith DJ. Pulmonary Wegener’s granulomatosis misdiagnosed as malignancy. *BMJ* 2001; 322: 89–90. doi: [https://doi.org/10.1136/bmj.322.7278.89](https://doi.org/10.1136/bmj.322.7278.89)
8. Faurschou M, Sorensen II, Mellemkjær L, Loft AGR, Thomsen BS, Tvede N, et al. Malignancies in Wegener’s granulomatosis:
incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. *J Rheumatol* 2008; 35: 100–5.

9. Heijl C, Harper L, Flossmann O, Stucker I, Scott D, Watts RA, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European vasculitis Study Group clinical trials. *Ann Rheum Dis* 2011; 70: 1415–21. doi: https://doi.org/10.1136/ard.2010.145250

10. Życinska K, Kostrzewa-Janicka J, Nitsch-Osuch A, Wardyn K. Cancer incidence in pulmonary vasculitis. *Adv Exp Med Biol* 2013; 788: 349–53. doi: https://doi.org/10.1007/978-94-007-6627-3_47

11. Shang W, Ning Y, Xu X, Li M, Guo S, Han M, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. *PLoS One* 2015; 10: e0126016. doi: https://doi.org/10.1371/journal.pone.0126016

12. Chemouny JM, Pagnoux C, Caudwell V, Karras A, Borie R, Guillevin L, et al. ANCA-Associated diseases and lung carcinomas: a five-case series. *Clin Nephrol* 2014; 81: 132–7. doi: https://doi.org/10.5414/CN107407

13. Abbass K, Krug H. Granulomatosis with polyangiitis in a patient with biopsy-proven IgG4-related pulmonary disease and coincident small cell lung cancer. *BMJ Case Rep* 2019; 12: pii: e226280. doi: https://doi.org/10.1136/bcr-2018-226280